Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Progress in targeting therapy for hepatic cancer]

J Uchino1, Y Une, T Kamiya

  • 1First Dept. of Surgery, Hokkaido University School of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 1, 1994
PubMed
Summary

Targeting therapies for liver cancer include Lipiodol drug carriers and immunotherapies. While Lipiodol is effective, novel strategies are needed to improve the accumulation of immune cells and immunoconjugates for better liver cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low dose antibiotic ingestion potentiates systemic and microbiome changes induced by silver nanoparticles.

NanoImpact·2022
Same author

Gastrointestinal: Superior mesenteric vein aneurysm treated using interventional radiology.

Journal of gastroenterology and hepatology·2022
Same author

Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2019
Same author

Maternal Separation Induces Orofacial Mechanical Allodynia in Adulthood.

Journal of dental research·2016
Same author

Alendronate does not prevent long bone fragility in an inactive rat model.

Journal of bone and mineral metabolism·2015
Same author

Authors' reply to Drs M van Blitterswijk, R Rademakers and LH van den Berg.

Neuropathology and applied neurobiology·2013

Area of Science:

  • Oncology
  • Drug Delivery Systems
  • Immunotherapy

Context:

  • Hepatic cancer treatment faces challenges with conventional chemotherapy's low response rates.
  • Current targeting strategies include Lipiodol as a drug carrier and monoclonal antibody-based immunotherapies.
  • Immunotherapy using cytotoxic cells has shown insufficient clinical efficacy for liver cancer.

Purpose:

  • To review current targeting therapy methods for hepatic cancer.
  • To highlight the effectiveness of Lipiodol as a drug carrier.
  • To identify the need for improved systems for accumulating cytotoxic cells or immunoconjugates in liver tumors.

Summary:

  • Lipiodol as a drug carrier is currently the most effective targeting therapy for hepatic cancer.
  • Immunotherapy approaches, including immuno-conjugates, have been explored but require enhancement.

Related Experiment Videos

  • Further investigation is needed to develop systems that effectively accumulate cytotoxic cells or immunoconjugates within liver tumor tissues.

    • Impact:

    • This research underscores the need for advanced therapeutic strategies in hepatic cancer treatment.
    • Optimizing the delivery and accumulation of therapeutic agents is crucial for improving patient outcomes.
    • Future research directions focus on enhancing the efficacy of immunotherapies for liver cancer.